BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Laser capture microdissection
,
Bleomycin
,
rs2300478
,
DNMT1
,
HIV infection
,
Retina
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
SynCAM2
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Substantia nigra pars compacta
Prefrontal cortex
Substantia nigra reticulata
Thalamus lateral nuclei
Frontal cortex
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
The CADM2 Gene and Behavior: A Phenome-Wide Scan in UK-Biobank.
MiR-17-5p Targets and Downregulates CADM2, Activating the Malignant Phenotypes of Colon Cancer Cells…
LINC01354 enhances the metastatic ability of gastric cancer cells by adjusting miR-153-5p/CADM2 expr…
ADAMTS9-AS2 and CADM2 expression and association with the prognosis in esophageal squamous cell carc…
Liver fibrosis-derived exosomal miR-106a-5p facilitates the malignancy by targeting SAMD12 and CADM2…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
There were no clinical trials for SynCAM2
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ